Diagnoses of the neurodegenerative disease, and rates of death from it, were each four times higher in the athletes than in the general U.S. male population, according to the study of more than 19,000 former and current NFL players who debuted between 1960 and 2019 and played at least one professional game.
The athletes were tracked for an average of 30 years after they started playing in the NFL. During that time, 38 received a diagnosis of ALS, and 28 died of it, the researchers reported in JAMA Network Open https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787180.
Those diagnosed with the disease had played pro football for about 2.5 years longer than those without ALS, suggesting an association between duration of NFL play and the disease, the researchers said.
The study could not identify the specific factors responsible for the higher rate of ALS in the players, however.
"The vast majority of cases of ALS are sporadic, meaning we don't know what caused the disease. This study provides further evidence that repetitive head impacts or concussion might increase risk of ALS," said the study's leader, Daniel Daneshvar of Harvard Medical School in Boston.
He added that repetitive head impacts could also come "from sport, military service, occupation, domestic violence, or any other cause."
The researchers noted that athletes' exposure at younger ages also "likely plays a role in the risk of neurodegenerative disease."
ALS is an invariably fatal neurologic disease in which the nerve cells that control movement progressively degenerate, leading to paralysis and death from respiratory failure. It is diagnosed in about 5,000 Americans each year.
Limitations to the study included the fact that researchers did not have access to players' medical records and had to depend on data collected in the past for other purposes.
SOURCE: https://bit.ly/3ISHswf JAMA Network Open, online December 15, 2021.
By Mrinalika Roy
Posted on
Previous Article
« CAR-T cell therapy for multiple myeloma may lead to Parkinson’s-like symptoms Next Article
Novel immunotherapy for cancer takes cue from transplant rejection »
« CAR-T cell therapy for multiple myeloma may lead to Parkinson’s-like symptoms Next Article
Novel immunotherapy for cancer takes cue from transplant rejection »
Related Articles
July 30, 2019
Subspecialty teleneurology: feasible and highly valued
September 10, 2020
Efficacy and safety of rituximab in refractory MG corroborated
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com